| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Elitra Pharmaceuticals, Inc. |
| 3510 Dunhill Street, San Diego, CA 92121 * (858) 410-3030 |
| Business Description | The company is a leader in antimicrobial functional genomics. The company uses proprietary technologies and molecular biology tools to identify the essential genes that enable bacteria and fungi to grow and survive. |
|
Filing Information IPO has been | |||
| To Trade As | ELIT (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 9/5/00 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $75,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Chase H&Q; | Lead Manager | (415) 439-3626 |
| U.S. Bancorp Piper Jaffray | Co-manager | (612) 342-6220 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | 6/30/99 | 6/30/00 | ||
| Revenues | - | - | 0.000 | 0.000 | 0.000 | 0.000 | 0.287 |
| Income from Oper. | - | - | -0.040 | -1.750 | -6.052 | -2.020 | -5.703 |
| Net Income | - | - | -0.041 | -1.749 | -5.786 | -2.042 | -5.523 |
| E.P.S | - | - | -0.110 | -2.550 | -4.520 | -1.710 | -2.930 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -4.67 | -1.87 | -4.45 | ||||
| Cash Flow - Inv. | -4.43 | -0.18 | -1.85 | ||||
| Cash Flow - Fin. | 15.67 | 15.95 | 4.66 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 6/30/00 | Financial Ratios | ||||
| Total Assets | 22.92 | Current Assets | 12.54 | Current Ratio | 3.85 |
| Total Liab. | 22.57 | Current Liab. | 3.26 | Debt Ratio | 98.51% |
| Total Equity | 0.34 | Working Cap. | 9.29 | Debt to Equity Ratio | 66.02 |
| Cash | 6.25 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development activities, access to complementary technologies, acquisition of compound and natural products libraries, patent prosecution and other capital investments, as well as working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Shearman & Sterling |
| Registrar/Transfer Agent | ChaseMellon Shareholder Services, L.L.C. |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Mayfield Fund | 16.80 | |
| Enterprise Partners | 16.40 | |
| Walden Group, The | 14.90 | |
| Interwest Partners | 13.30 | |
| Incyte Genomics, Inc. | 5.40 | |
| Note: represents ownership of 5% or more prior to the offering. | ||